

### Utilization Report

Invention Report #: 7654321-06-0034  
Primary Agency: NIH

Docket Number: 06-0034  
Report Date: 07/22/2006

Institution: DAN'S INSTITUTION (7654321)  
Title: lkhgikjgikj

Submit Reset

#### Invention/Patent/Utilization Tree

#### Preliminary Utilization Questions

Please complete the following Preliminary Utilization Questions in order. The responses to the Preliminary Utilization Questions will determine the Utilization Questions that will be generated.

1. Choose Invention \* *Choose Invention* 2. Reporting Year (YYYY) \* *Reporting Year* 3. Development Stage \* *Development Stage*

7654321-06-0034 2023

\* Please indicate the latest stage of development of any product arising from this invention, according to the above categories.

#### Utilization Questions

#### NIH Supplemental Questions

Please provide the commercial name of any FDA-approved products, utilizing this invention, that are currently marketed or planned for marketing during the reporting period. Please note: Commercial names should be limited to FDA-approved products that first reached the market during the designated reporting period. Please remove the "Public" checkmark from any FDA-approved product that you do not want to appear on a publicly available list of products arising from your funding agreement.

#### Commercial Products

Product	FDA Approval Number	FDA Approval Type	Public (Y/N)	Government Review Status	Report Date
---------	---------------------	-------------------	--------------	--------------------------	-------------

### Utilization Report

Invention Report #: 7654321-06-0034  
Primary Agency: NIH

Docket Number: 06-0034  
Report Date: 07/22/2006

Institution: DAN'S INSTITUTION (7654321)  
Title: lkhgikjgikj

Submit Reset

#### Invention/Patent/Utilization Tree

#### Preliminary Utilization Questions

Please complete the following Preliminary Utilization Questions in order. The responses to the Preliminary Utilization Questions will determine the Utilization Questions that will be generated.

1. Choose Invention \* *Choose Invention* 2. Reporting Year (YYYY) \* *Reporting Year* 3. Development Stage \* *Development Stage*

7654321-06-0034 2023

Commercialized  
Licensed  
Not Licensed or Commercialized

#### Utilization Questions

#### NIH Supplemental Questions

#### Preliminary Utilization Questions

Please complete the following Preliminary Utilization Questions in order. The responses to the Preliminary Utilization Questions will determine the Utilization Questions that will be generated.

1. Choose Invention \* *Choose Invention* 2. Reporting Year (YYYY) \* *Reporting Year* 3. Development Stage \* *Development Stage*

7654321-06-0034 2023 Not Licensed or Commercialized

\* Please indicate the latest stage of development of any product arising from this invention, according to the above categories.

#### Utilization Questions

4. What are your current commercialization plans for this invention? \*

Dropdown menu for commercialization plans

Notes

Text area for notes

1000 characters remaining

### Preliminary Utilization Questions

Please complete the following **Preliminary Utilization Questions** in order. The responses to the **Preliminary Utilization Questions** will determine the **Utilization Questions** that will be generated.

1. Choose Invention \* *Choose Invention*  
7654321-06-0034

2. Reporting Year (YYYY) \* *Reporting Year*  
2023

3. Development Stage \* *Development Stage*  
Not Licensed or Commercialized

\* Please indicate the latest stage of development of any product arising from this invention, according to the above categories.

### Utilization Questions

4. What are your current commercialization plans for this invention? \*

- Seeking additional funding to further develop this invention
- Marketing and/or furthering development of this invention to attract commercial partners
- Developing and/or preparing this invention with intent to commercialize ourselves
- Making available for distribution and/or licensing for research purposes only

### Utilization Questions

4. In the designated reporting period, how many exclusive licenses and/or options are or were active? \*

0

\* Please input the number of exclusive licensees and the Add Licensee(s) Dialog popup will allow you to input the licensee name(s). Any subsequent licensee names can be added with the Add Exclusive Licensee button.

#### Exclusive Licensee Name

0 exclusive licensee names

(1 of 1)

<< < > >>

All ▾

+ Add Exclusive Licensee

5. In the designated reporting period, how many non-exclusive licenses and/or options are or were active? \*

0

\* Please input the number of non-exclusive licensees and the Add Licensee(s) Dialog popup will allow you to input the licensee name(s). Any subsequent licensee names can be added with the Add Non-Exclusive Licensee button.

#### Non-Exclusive Licensee Name

0 non-exclusive licensee names

(1 of 1)

<< < > >>

All ▾

+ Add Non-Exclusive Licensee

### Utilization Questions

4. In the designated reporting period, how many exclusive licenses and/or options are or were active? \*

2

\* Please use the Add Exclusive Licensee button to add a licensee.

#### Exclusive Licensee Name

0 exclusive licensee names

(1 of 1)

<< < > >>

All ▾

+ Add Exclusive Licensee

5. In the designated reporting period, how many non-exclusive licenses and/or options are or were active? \*

0

\* Please input the number of non-exclusive licensees and the Add Licensee(s) Dialog popup will allow you to input the licensee name(s). Any subsequent licensee names can be added with the Add Non-Exclusive Licensee button.

#### Add Licensee

Licensee Name(s) \*

5. In the designated reporting period, how many non-exclusive licenses and/or options are or were active? \*

7

\* Please use the Add Non-Exclusive License button to add a licensee.

Non-Exclusive Licensee Name

0 non-exclusive licensee names

(1 of 1) << < > >> All

+ Add Non-Exclusive Licensee

Add Licensee

X

Licensee Name(s) \*

Cancel Save

6. In the designated reporting period, how many licenses and/or options of any type to small businesses (as defined by relevant SBA regulations) are or were active? \*

7. In the designated reporting period, what was the total gross income received as a result of license or option agreements? \*

Do not include specific patent cost reimbursements

8. Other than U.S. Preference (35 U.S.C. 204), is the invention subject to any U.S. manufacturing requirements (e.g. U.S. Competitiveness provision, a U.S. Manufacturing DEC, etc.)? \*

Notes

1000 characters remaining

6. In the designated reporting period, how many licenses and/or options of any type to small businesses (as defined by relevant SBA regulations) are or were active? \*

7. In the designated reporting period, what was the total gross income received as a result of license or option agreements? \*

Do not include specific patent cost reimbursements

8. Other than U.S. Preference (35 U.S.C. 204), is the invention subject to any U.S. manufacturing requirements (e.g. U.S. Competitiveness provision, a U.S. Manufacturing DEC, etc.)? \*

Yes

No

1000 characters remaining

8. Other than U.S. Preference (35 U.S.C. 204), is the invention subject to any U.S. manufacturing requirements (e.g. U.S. Competitiveness provision, a U.S. Manufacturing DEC, etc.)? \*

No

9. In the designated reporting period do all grants to any person of the exclusive right to use or sell the subject invention in the United States require that any products embodying the subject invention or produced through the use of the subject invention will be manufactured substantially in the United States as required by 35 U.S.C. 204? \*

Notes

1000 characters remaining

8. Other than U.S. Preference (35 U.S.C. 204), is the invention subject to any U.S. manufacturing requirements (e.g. U.S. Competitiveness provision, a U.S. Manufacturing DEC, etc.)? \*

Yes

9. In the designated reporting period, do all licenses include a requirement that any products embodying the subject invention or produced through the use of the subject invention will be manufactured substantially in the United States (including manufacturing requirements other than 35 U.S.C. 204)? \*

Notes

1000 characters remaining

8. Other than U.S. Preference (35 U.S.C. 204), is the invention subject to any U.S. manufacturing requirements (e.g. U.S. Competitiveness provision, a U.S. Manufacturing DEC, etc.)? \*

No

9. In the designated reporting period do all grants to any person of the exclusive right to use or sell the subject invention in the United States require that any products embodying the subject invention or produced through the use of the subject invention will be manufactured substantially in the United States as required by 35 U.S.C. 204? \*

10. In the designated reporting period are all products embodying the subject invention or produced through the use of the subject invention manufactured substantially in the United States for all grants to any person of the exclusive right to use or sell the subject invention in the United States as required by 35 U.S.C. 204? \*

11. What was the calendar year of the first commercial sale? \*

12. List any products made through the use of or embodying the subject invention(s).

(0 Commercial products found)

[+ Add Commercial Product](#)

Notes

8. Other than U.S. Preference (35 U.S.C. 204), is the invention subject to any U.S. manufacturing requirements (e.g. U.S. Competitiveness provision, a U.S. Manufacturing DEC, etc.)? \*

Yes

9. In the designated reporting period, do all licenses include a requirement that any products embodying the subject invention or produced through the use of the subject invention will be manufactured substantially in the United States (including manufacturing requirements other than 35 U.S.C. 204)? \*

10. In the designated reporting period, are all products embodying the subject invention or produced through the use of the subject invention manufactured substantially in the United States (including manufacturing requirements other than 35 U.S.C. 204)? \*

11. What was the calendar year of the first commercial sale? \*

12. List any products made through the use of or embodying the subject invention(s).

(0 Commercial products found)

[+ Add Commercial Product](#)

Notes

## Add Product



Product Name \*

Licensee(s) \*

0 licensees found

[+ Add Licensee and Manufacturers](#)

[Cancel](#)

[Save](#)

### Add Licensee

Licensee Name \*

Select licensee

Manufacturer(s) \*      Location(s)

0 manufacturers found

+ Add Manufacturers

Cancel Save

### Add Manufacturer

Manufacturer Name \*

US States and Territories (\*)

Please select...

Countries Outside US (\*)

Please select...

*Please select at least 1 location from US States and Territories or Countries Outside US*

Save

### NIH Supplemental Questions

Please provide the commercial name of any FDA-approved products, utilizing this invention, that have first reached the market during the designated reporting period.

**Please note:** Commercial names should be limited to FDA-approved products that first reached the market during the designated reporting period. Please remove the "Public" checkmark from any FDA-approved product that you do not want to appear on a publicly available list of products arising from your funding agreement.

Commercial Products

Product	FDA Approval Number	FDA Approval Type	Public (Y/N)	Government Review Status	Report Date
0 products found					

+ Add FDA Approved Commercial Product

## Add FDA Approved Commercial Product



Product Name \*

FDA Approval Number

Commercial Product Type

Government Review Status

Publicly Announced

Yes  No

 Cancel

 Save

### DOE Supplemental Questions

Approximate number of new US-based jobs created because of commercialization efforts during the reporting period.

Number of new US-based companies created from the commercialization efforts during the reporting period.

Unique Commercial Products Made Through the Use of or Embodying the Subject Inventions. Please note, for each product also list the associated NAICS code (if applicable).

(0 manufacturing products found)

Unique Commercial Products Made Through the Use of or Embodying the Subject Inventions. Please note, for each product also list the associated NAICS code (if applicable).

### Great New Product

NAICS Code

Licensee	Manufacturer	Location	Quantity *	First Manufacture Date *	Actual/Expected *
ABC	EDF Manufacturing	US, ALABAMA	<input type="text"/>	<input type="text"/>	<input type="text"/>
		UNITED KINGDOM	<input type="text"/>	<input type="text"/>	<input type="text"/>

